MYC and cancer: Therefore, utilizing a small molecular drug to inhibit PVT1, compared to treatment that directly targets MYC, would fine-tune the level of c-Myc in cancer and reduce toxic side effects or exert an influence on the c-Myc downstream biological phenotype, which is another therapeutic target in MYC-driven cancer.